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Scientific opinion on the relationship between selenium and the risk of cancer has un-
dergone radical change over the years, with selenium first viewed as a possible car-
cinogen in the 1940s then as a possible cancer preventive agent in the 1960s–2000s.
More recently, randomized controlled trials have found no effect on cancer risk but
suggest possible low-dose dermatologic and endocrine toxicity, and animal studies indi-
cate both carcinogenic and cancer-preventive effects. A growing body of evidence from
human and laboratory studies indicates dramatically different biological effects of the
various inorganic and organic chemical forms of selenium, which may explain apparent
inconsistencies across studies. These chemical form-specific effects also have important
implications for exposure and health risk assessment. Overall, available epidemiologic
evidence suggests no cancer preventive effect of increased selenium intake in healthy
individuals and possible increased risk of other diseases and disorders.
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INTRODUCTION
Few health issues have elicited as intense debate as the relationship between
selenium (Se) and the risk of cancer [1–4]. Synthesizing the scientific evidence
on the Se-cancer relationship is difficult—there is a large abundance of lit-
erature reporting effects ranging from nutritional to toxic even for the same
chemical form of Se, amount of exposure, and target species [2, 5]—and car-
ries the risk of being labeled a selenophobic [6] or a selenophilic [7], depending
on one’s conclusions. Yet attempts to reconcile the current evidence are criti-
cally important, not only to meet the information needs of key stakeholders,
including the general population and regulatory agencies, but also because the
attempt can yield important lessons for epidemiology, public health, and oncol-
ogy. The time trend in the number of Medline-indexed citations returned when
using the search terms “selenium” and “cancer” indicates an enduring interest
in this issue (Figure 1).
Debates about the health effects of particular substances are not unusual
in biomedical research, but the disputes surrounding Se have been particularly
heated. At various time points in recent history, Se has been hypothesized to
be a carcinogen, a cancer preventive agent, a cancer therapeutic agent, and
to have no effect on human cancer. The suggestion of opposite effects of Se on
health is not confined to cancer. Se has been shown to have both antioxidant
and pro-oxidant activity [5], to be both neuroprotective and neurotoxic [8], a
cardiovascular health promotor as well as a cardiovascular health risk factor
[9], and has been suggested to be both an antidiabetogenic and a prodiabeto-
genic agent [10]. Overlaid on this confusing state of affairs is the fact that Se
Figure 1: Number of publications per year yielded a Medline search using the terms
“selenium” and “cancer” (solid line) and “selenium,” “cancer,” and “humans” (dotted line).
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is an essential nutrient for humans; it is a constituent of more than 20 seleno-
proteins that play critical roles in reproduction, thyroid hormone metabolism,
DNA synthesis, and protection from oxidative damage and infection [11].
The aims of this review are to briefly summarize past literature to pro-
vide historical perspective and critically evaluate the most recent findings on
the Se-human cancer relationship emerging from epidemiologic and clinical
studies and their coherence with laboratory evidence. We also briefly discuss
exposure limits for Se and the prospects for Se as a cancer therapeutic agent.
EARLY LABORATORY STUDIES ON SE AND CANCER
Se was first implicated in the etiology of cancer in 1943 by the seminal study of
Nelson and colleagues, who reported its ability to promote liver cell adenoma
and carcinoma in rats [12]. This was followed by other reports of carcinogenic
effects [13, 14], but also several studies in laboratory animals suggesting the
ability of Se to inhibit cancer cell growth [15], leading to a large literature on
the ability of Se compounds to inhibit cancer progression [1, 16]. More recent
laboratory investigations have also found evidence of both cancer-enhancing
and cancer-inhibiting effects of Se, depending on the amount of exposure and
chemical forms [17–20].
EARLY ECOLOGIC STUDIES ON SE AND CANCER
The first hypothesis concerning the relationship of Se and human cancer arose
from ecologic studies carried out in the United States and were published
starting in the late 1960s. These investigations, initiated by Shamberger and
colleagues [21, 22] and followed by others [23–26], consistently suggested an
inverse association between environmental indicators of Se exposure such as
forage and water Se levels or population levels of human biomarkers (Se di-
etary intake or blood levels) and area-level cancer rates, and were the first
studies to bring the possible relationship between Se intake and cancer risk to
the attention of the scientific community and the general public. Surprisingly,
the weaknesses of such studies, inherent in their ecologic study design, were
given little attention, and these data, together with animal studies suggest-
ing a cancer preventive effect, had a major role in promoting the hypothesis of
cancer chemoprevention by selenium.
Most ecologic studies of the Se-cancer relationship, particularly the earlier
ones [27], had little or no control of potential confounders, and had indicators
of community-level Se exposure that were of questionable reliability. More re-
cent studies have had improved control of confounders [2, 27], and also found
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inverse relationships between Se exposure and risk of several site-specific can-
cers as well as overall cancer risk; however, the large potential for bias as-
sociated with ecologic study designs remains. Findings from ecologic studies
have not been uniformly in favor of cancer chemoprevention. A direct associa-
tion with environmental indicators of Se exposure has been suggested for some
site-specific cancers, such as leukemia and lymphoma [26]. More recently, and
unexpectedly, direct association between Se exposure indicators and cancer
risk have been suggested by other ecologic studies, such as a direct association
between breast cancer mortality and serum Se levels in 65 Chinese rural coun-
ties [28] and between esophageal cancer incidence and soil Se in northeastern
Iran [29], in contrast with other recent reports [30], further highlighting the
need for caution in evaluating the validity and reliability of the results of such
studies.
In the case of Se, the weaknesses of ecologic studies far exceed those of
most ecologic studies. Se local water, soil, and forage content has little influ-
ence on the Se exposure of local residents, since most individuals, particularly
in Western countries including the United States, do not consume mainly lo-
cally produced foodstuffs, and therefore their diet is not directly influenced by
local soil Se. Further, water Se levels may vary considerably across local wells
even in very small areas, thus precluding reliable evaluation of local exposure
using geographical aggregate estimates. In addition, other factors such as oc-
cupational exposures, smoking habits, and intake of methionine may greatly
influence Se intake and bioavailability, further weakening the reliability of
any epidemiologic studies based on aggregate assessment of exposure and out-
comes.
THE NEXT STAGE: COHORT AND CASE-CONTROL STUDIES
Following the early ecologic studies, numerous observational studies with
individual-level Se exposure assessment were conducted [2, 27]. Many of these
studies had a prospective design, for example, a cohort-nested case-control
study design, in an attempt to avoid one of the most common weaknesses of
case-control studies, reverse causality—a disease-induced change of Se status.
However, as we describe, exposure assessment is still a major issue for such
studies, limiting their value in resolving the Se-cancer relationship. Given its
importance, we first discuss exposure assessment issues for such studies.
Many individual-level epidemiologic studies have used biological indi-
cators of exposure, generally toenail or blood Se content or whole blood
glutathione-peroxidase activity, in specimens collected at baseline to assess
overall Se exposure [2, 31]. A limitation of these common biomarkers is that
Se content in specific compartments such as blood or toenails may not repre-
sent levels of Se species in tissues relevant to cancer risk; in this, we can take a
lesson from studies of the Se distribution in the human central nervous system
Selenium and Human Cancer Risk 309
Table 1: Median Values (μg/l) of Se Chemical Species Identified in Blood (Serum)
and Cerebrospinal Fluid (CSF) of 24 Human Subjects, with Their Squared Correlation
Coefficients (r2) (Published and Unpublished Data from Solovyev, Berthele, and
Michalke [32])
Se Species Serum CSF r2
Se-cysteine <LoD1 <LoD
Selenoprotein P 5.19 0.474 0.037
Glutathione peroxidase 4.27 0.036 0.384
Se-methionine 0.23 <LoD
Thioredoxin reductase 1.64 0.035 0.629
Human serum albumin Se (HSA-Se) 18.03 0.068 0.172
Selenite 12.25 0.046 0.040
Selenate <LoD <LoD 0.009
UF2–1 <LoD <LoD
UF-2 <LoD <LoD
UF-3 <LoD <LoD
UF-4 6.34 <LoD
Total 58.39 0.861 0.0002
1Limit of detection.
2Unknown form.
[8, 32], which have found that Se concentrations in cerebrospinal fluid may be
uncorrelated with peripheral circulating Se levels (Table 1).
Estimation of Se dietary intake has also been used for exposure assess-
ment. This approach has been considered by some investigators as less reliable
than biological indicators, due to large variations of Se content in foodstuffs
over space and time, individual differences in absorption, and the role of other
sources of exposure, that is, dermal absorption and inhalation (e.g., with smok-
ing, in occupational environments, or in coal-polluted areas). However, many
epidemiologic studies [33–37], although not all [38–40], have found that esti-
mated Se dietary intake is correlated with tissue level, such as blood or toenail
Se content. It could be argued that dietary intake is superior to Se tissue con-
tent as an indication of exposure, since the different Se species are retained at
very different rates in the body and they also modify their biological activity on
the basis of concurrent intake of dietary factors such as methionine and other
elements such as Zn, Hg, and Cd [5, 41]. Furthermore, lower persistence of
some Se species in the body compared with others does not per se indicate less
biological availability or lower toxicity, since carefully conducted studies in an-
imals have demonstrated that Se retained in the body after administration of
its inorganic forms can be more toxic than Se administered as organic species,
for equivalent amounts of intake [42, 43]. Under this perspective, careful as-
sessment of Se intake from diet and other sources and whenever possible its
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speciation would allow a better estimate of actual exposure than simple deter-
mination of overall Se content through biomarkers, which is mainly influenced
by intake of organic Se.
Exposure assessment using Se-containing enzymes such as plasma
selenoprotein-P or whole blood glutathione-peroxidase activity has also been
suggested [44]. Each such indicator has particular strengths and limitations;
however, in general, the use of indirect indicators such as Se-containing en-
zymes has serious limitations, since the relationship between their tissue lev-
els and Se exposure is complex and not well-defined, is heavily influenced by
other dietary factors, and is inducible by factors such as oxidative stress (in-
cluding Se itself) [5, 45–48].
We now turn to the findings of these case-control and observational cohort
studies, originally designed to elucidate the promising findings of the ecologic
investigations and some of the laboratory studies. A huge number of these
studies have been carried out in different countries and populations, and most
of them have found either inverse or null associations between baseline Se ex-
posure and subsequent cancer risk [2, 49–52], while a few have reported direct
associations for specific cancer sites [53–58]. For prostate cancer, in particular,
most though not all studies have indicated a beneficial effect of Se [2, 50]. The
reasons of such inconsistencies are unclear. They cannot be readily ascribed to
differences in Se exposure levels, since even in populations in the lower range
of exposure, inverse, null, and direct associations have been found for the same
cancer site, for example, lung cancer [57–60]. Unmeasured confounding is a
key methodological issue that may explain these conflicting results of obser-
vational studies, despite the efforts of investigators to adjust for or stratify
on measured potential confounders. Unmeasured confounding is a well-known
problem in nutritional epidemiology due to the large number of dietary and
lifestyle factors, which may co-vary with the primary variables under study or
act as effect modifiers. However, the dietary or lifestyle factors responsible for
the inconsistencies among observational studies have not been convincingly
identified. Another important methodological issue that may explain these in-
consistencies is exposure misclassification. Most observational studies have
been based on determination of total Se in peripheral biomarkers such as blood
(generally plasma or serum) or toenails. However, Se may be found in environ-
mental matrices, including foods, usually by far the main source of exposure,
as organic and inorganic compounds [3, 61], and these different chemical forms
of Se have different and in some cases even opposite toxicological and nutri-
tional effects [5, 62–70]. Moreover, some dietary factors such as methionine
and trace elements such as heavy metals may considerably modify Se biologi-
cal activity and metabolism [41, 42, 71, 72], and the chemical forms of Se may
influence its distribution in different body tissues [27, 32, 73–75]; in addition,
the levels found in some body tissues may not correlate with those detected
by other biological indicators. Taking into account all these aspects, lack of
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determination of specific Se species in target organs/tissues for disease on-
set, and of other circulating factors influencing Se biological activity, may
have created substantial misclassification of exposure, which, in the worse
cases—particularly for Se compounds having lower concentrations but the
highest toxicological activity such as the inorganic forms selenite and selenite
[76–78]—may have biased the overall results. On the other hand, analytical
methodologies for determination of individual Se species have only recently
been developed [32, 79, 80] and are complex, expensive, and time-consuming.
In case-control investigations based on biomarkers, exposure misclassification
may also have been generated by an effect of disease itself (particularly at its
advanced stages) on Se biological indicators, generally inducing a decrease in
circulating Se levels but in some instances increasing Se concentrations (as
the neoplastic tissue). This raises the issue of reverse causality, whose risk is
inherent in this type of studies. Finally, an additional possible explanation of
the different findings may be the different genetic compositions of the under-
lying populations, since variants of genes coding selenoproteins might modify
the risk of cancer, as well as of cancer survival, associated with Se exposure
[81–83]. Specific genotypes may modify the selenium-human cancer associa-
tion [51] and may even switch Se from being protective to being detrimental in
influencing cancer risk [84, 85].
MOVING FORWARD: RANDOMIZED CONTROLLED TRIALS
Considering the conflicting results of observational studies and their limita-
tions, and the strong chemopreventive effect of Se suggested by some of them,
it is no surprise that randomized controlled trials (RCTs) were designed to con-
firm such findings. The key features of these studies and their main results are
summarized in Table 2 and Figure 2a–c.
Some trials have been designed as multiple intervention cohort studies, ad-
ministering other trace elements and vitamins or different substances [86–89]
to participants in addition to Se, thus precluding identification of its specific
activity. Other experimental studies having a “community” design selectively
focused on Se activity but were characterized by lack of adequate information
about potential confounders or individual-based follow-up and ascertainment
of both exposure and outcome [90–92], thus hampering interpretation of re-
sults. We therefore do not take these studies into further consideration in the
present review. Rather, we focus on RCTs that were specifically designed to
estimate the effects of Se administration on cancer risk, the majority of which
were carried out in specific patient populations in the United States [93–97]
and in France [98], and in one case in the general U.S. population [99, 100].
The patient populations involved in such studies were nonmelanoma skin can-
cer patients [93–95], individuals at high risk of prostatic neoplasm [96, 97] or
breast cancer [101], and organ transplant recipients [98]. Among these trials,
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the two largest, the Nutritional Prevention of Cancer (NPC) Trial and the Se-
lenium and Vitamin E Cancer Prevention Trial (SELECT), have received the
greatest attention from both the general population and the scientific commu-
nity. We discuss these trials in detail.
The Nutritional Prevention of Cancer (NPC) Trial
The NPC trial [93–95, 102–104] was designed to test the hypothesis that
dietary supplementation with Se at 200 μg/day may decrease cancer risk. The
study participants (n = 1312) were patients with recent (1-year) diagnosis of
basal or squamous cell skin cancer, life expectancy of at least 5 years, and no
treatment for internal cancers in the past 5 years. Se was administered as
selenized baker’s yeast, which contains organic Se in the form of selenomethio-
nine (∼60%) and other selenoproteins [103]. The primary outcomes were the
incidence of basal cell and squamous cell skin cancer; secondary outcomes in-
cluded incidence of all cancers and of some major site-specific cancers. Patient
recruitment occurred in 1983–1991, and the official end of the blinded treat-
ment period was February 1, 1996. Final results were published in 2002–2003
[93–95]. A preliminary analysis was published in 1996 based on follow-up data
Figure 2: Relative risk (RR) for selected cancers in randomized, placebo-controlled trials (with
200 μg of organic Se when not otherwise specified; see Table 2 for references numbers).
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Figure 2: (Continued)
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through December 1, 1993, following the recommendation of the trial’s Safety
Monitoring and Advisory Committee in 1994 to unblind the study and present
the results for the first 10-year period [102]. We focus on the final results,
which are based on longer follow-up.
The final results of the NPC trial, reported in Table 2 and Figure 2a–c,
are complex to interpret. There was an excess risk of squamous cell carci-
noma (RR 1.25, 95% CI 1.03–1.51) and a slightly increased risk of basal cell
carcinoma (RR 1.09, 95% 0.94–1.26), yielding an excess risk of overall non-
melanoma skin cancer of 17% (95% CI 2%–34%) and leading to the conclu-
sion that Se increased the risk of total nonmelanoma skin cancer [94]. In
contrast, the risk of all cancers (RR 0.75, 95% CI 0.58–0.97), prostate (RR
0.48, 95% CI 0.28–0.80), lung (RR 0.74, 95% CI 0.44–1.24), and colorectal
(RR 0.46, 95% CI 0.21–1.02) cancers [93, 103] was decreased. For lung can-
cer, an analysis according to baseline plasma Se showed that the inverse as-
sociation was confined to subjects in the lowest tertile, which was <106 μg/l
[103]. Some cancer sites suggested an increased risk associated with Se sup-
plementation, but estimates were generally statistically unstable due to the
low number of cases: among these were breast cancer (RR 1.89, 95% CI
0.69–5.14) and, with much lower RRs, melanoma, bladder, and lymphoma and
leukemia. Further analyses on prostate cancer revealed very different RRs ac-
cording to baseline plasma Se, ranging from RR values as low as 0.14 (95%
CI 0.03–0.61) among subjects in the lowest tertile of plasma Se (≤106.4 μg/l)
up to 1.14 (95% CI 0.51–2.59) for plasma Se >123.2 μg/l, but the risk re-
duction was nearly entirely confined to subjects with prostate specific anti-
gen (PSA) ≤4 ng/ml [95]. In addition, further analysis stratified by treatment
arm showed a weak inverse association between baseline Se and subsequent
prostate cancer risk among placebo participants but a direct association among
Se-treated participants [105]. After adjusting for some differences between
treatment groups, the positive association between Se administration and
prostate cancer risk remained strong [105], thus suggesting an increased risk
among subjects with higher baseline plasma Se, in sharp contrast to the pre-
liminary results of the trial [102] and the findings in placebo-treated subjects
[105].
The NPC results, particularly the preliminary ones, received widespread
attention from both the public and the scientific community (more than 2500
citations in Google Scholar for its first 1996 report as of July 2013), with em-
phasis placed on the “beneficial” findings for all cancers and prostate cancer
incidence and the concerning results for the primary outcome, nonmelanoma
skin cancer, either overlooked or dismissed. This lack of attention proba-
bly occurred because such results were not consistent with preexisting ex-
pectations: Se was one of most promising dietary factors in chemopreven-
tion, the first prospective studies carried out during the 1980s had suggested
an association between Se exposure indicators at baseline and subsequent
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cancer risk [60, 106–109], and Se had proven effective in inhibiting can-
cer cell growth in several animal models (although such reasoning ignored
the carcinogenic activity of some Se compounds suggested by a few of these
studies).
The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
The SELECT trial was a large-scale attempt to evaluate the activity of two
promising chemopreventive agents, Se and vitamin E, for prostate cancer pre-
vention [110–112]. This trial recruited more than 35,000 men from 427 sites in
the United States, Canada, and Puerto Rico; eligibility criteria were ≥50 years
for black men and ≥55 for all others, a PSA value of 4.0 ng/l or less, and a
digital rectal examination not suspicious for prostate cancer. Recruitment was
from August 22, 2001 through June 24, 2004, and three reports of the study
results have been published to date: one concerning the main outcomes after
follow-up to Oct 23, 2008 [99], the second one updating the results with an
(unblinded) follow-up until July 5, 2011 [100], and the third one reporting RR
of bladder cancer [113].
SELECT study participants were randomized to oral Se as selenomethio-
nine (200 μg/day), vitamin E, Se plus vitamin E or placebo. The Se only and
placebo arms included 8752 and 8696 patients who could be included in the pri-
mary analysis, respectively, and who were also followed in the updated follow-
up with a person-time increase of 23%. The follow-up was extended beyond
the primary outcome, prostate cancer incidence, to include cardiac events, di-
abetes, severe or life-threatening (grade 3 or 4) events, and minor side effects
potentially related to the study supplements: alopecia, dermatitis, fatigue, hal-
itosis, nail changes, and nausea. The originally planned minimum and maxi-
mum follow-up was 7 and 12 years, but the actual average follow-up periods
were 5.5 years until the end of the blinded follow-up with discontinuation of
Se supplementation and 7.1 until the end of subsequent follow-up to report
additional postexposure events [99, 100]. This shorter follow-up compared to
that originally planned was due to an unanticipated interruption of the trial,
due to the recommendation of the independent Data Safety Monitoring Com-
mittee to discontinue the study because of its inefficacy in risk reduction and
concern about increased risk of prostate cancer in vitamin E-supplemented
participants and of type 2 diabetes in the Se-treated participants [99, 100], an
observation that echoed the marked increase in diabetes risk observed after Se
administration in the NPC trial [114].
Overall, the results of the SELECT trial, summarized in Table 2 and Fig-
ure 2a–b, have so far provided strong evidence against any cancer-prevention
effect in this study population [115]. Overall relative risk of cancer was 1.01
(99% CI 0.89–1.15), with a slightly and statistically imprecise increased risk
of prostate cancer (RR 1.04, 99% CI 0.87–1.24), lung cancer (RR 1.12, 99% CI
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0.73–1.72), and colorectal cancer (RR 1.05, 99% CI 0.66–1.67), and little evi-
dence of altered risk for the other primary neoplasms (excluded nonmelanoma
skin cancer) (RR 0.99, 95% CI 0.77–1.17) [99, 100]. An analysis limited to the
risk of aggressive prostate cancer (Gleason score ≥7) showed an excess risk of
high-grade disease among Se-treated subjects (RR = 1.21, 99% CI 0.90–1.63)
[100], this possibly being the most concerning finding of the SELECT study
[115].
Bladder cancer incidence, despite being one of the site-specific cancers
most strongly associated with Se status in observational cohort studies, was
not decreased by Se treatment but rather was slightly increased (RR 1.13),
although the estimate was statistically very imprecise (99% CI 0.78–1.63)
[113].
NPC vs. SELECT: Why the Conflicting Results?
Why did the Se-supplemented participants in the NPC trial exhibit a re-
duced risk of cancer while those in the second larger SELECT trial did not?
One possibility is the underlying difference in populations; the NPC trial en-
rolled patients with nonmelanoma skin cancer whereas the SELECT trial par-
ticipants, although male only, more closely resembled the general population,
presenting the possibility of specific risk factors or behavioral profiles interact-
ing with Se to modify some cancer preventive effect.
Another possibility is the different ranges of Se exposure in the two study
populations, with the patients enrolled in NPC exhibiting a lower average
exposure than SELECT participants. This hypothesis is interesting but un-
convincing for several reasons. The first is the small difference in median
intake between the two populations, of about 23 μg/l, which corresponds to
about 15 μg/day in dietary intake [116], a small difference when compared to
the large range of intake across different Western populations, ranging from
an average of 20–40 μg/day in Italian, Austrian, and French populations to
≥100 μg/day in some U.S. and Japanese populations (excluding supplements)
[116–118]. Under the same perspective, the very different results obtained in
the NPC across tertiles of plasma Se for all cancers and for prostate cancer risk
in Se-treated subjects, ranging from –76% in the bottom category to +14% in
the highest category despite an inter-tertile range as small as 16.8 μg/l (around
11 μg/day of dietary Se intake), make it biologically implausible to ascribe such
extreme variations in cancer RR to such small differences in exposure, unless
we assume that 120 μg/l of plasma Se represents a critical threshold for can-
cer risk. Any small change of a few μg of dietary Se intake from this amount
would therefore imply remarkable changes in cancer risk, but no such effects
have ever been described in ecologic or individual-based epidemiologic studies
despite variations in individual intakes that range into the hundreds of mi-
crograms. This hypothesis also finds little support from observational studies
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concerning the effects of Se supplementation in populations with much lower
average intakes of Se, such as the trends in prostate cancer incidence in Fin-
land following nationwide Se supplementation compared with other Nordic
countries, which did not show any beneficial effect [27]; from the lack of any
reduction in mortality from prostate cancer within an Italian population natu-
rally exposed to inorganic hexavalent Se [119]; and from the results of a recent
phase III trial by Marshall and colleagues in high-risk individuals for prostate
cancer, focusing on RRs observed in those with baseline plasma Se in the <106
and 106–132 μg/l categories [96].
Further weakening the possibility that such small differences in average
intake may explain the different results of the two trials is the observation
that toxicity of the Se supplements occurred in both the NPC and SELECT
trials: an excess risk of glaucoma and diabetes in the NPC study [114, 120],
and of dermatologic abnormalities and diabetes in the SELECT trial [99], the
latter being one of the reasons for interrupting the trial; the risk of diabetes
subsequently decreased following discontinuation [100]. Occurrence of toxicity
indicates a comparable activity of Se in the two trials, an observation that
weakens the hypothesis of marked differences in exposure.
To facilitate interpretation of the results of the two trials, some further
analyses of the SELECT trial data would be highly informative. In particular,
we urge analyses as to whether the overall risk of cancer and risk of site-
specific cancers varies by baseline Se exposure level, and whether the risk of
nonmelanoma and melanoma skin cancer is associated with Se supplementa-
tion [94, 98, 121].
Last, a potentially severe bias has been acknowledged by the NPC trial
investigators, and it may at least partially explain the impressive results
obtained in that trial for prostate cancer and subsequently unconfirmed by
the other experimental studies [95, 96]. For unknown reasons, presumably by
chance, the NPC participants randomized to Se were later found to have been
less biopsied than individuals on placebo following a PSA test at baseline or
in the follow-up (14% vs. 35% in the Se and placebo groups, respectively) [95,
96], thus exposing the Se supplementation arm of the trial to risk of under-
detection of prostate cancer. The investigators tried to adjust the analysis for
this potentially serious bias [95], but the extent to which this bias may have
occurred is unclear and remains a critical limitation of the NPC study. A role
of unmeasured confounders and of the limitations of secondary analyses (all
outcomes other than nonmelanoma skin cancer primary occurrence) have also
been hypothesized as potentially explaining at least some of the beneficial re-
sults on prostate cancer reported by the NPC trial [96]. However, these factors
are unlikely to fully explain the trial results since ascertainment of the sec-
ondary outcomes was apparently satisfactory and unbiased in the NPC trial,
and since claims about limitations of multiple comparisons are not convincing
from an epidemiologic perspective [122].
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Other Randomized Controlled Trials
A small ancillary study of NPC, involving patients enrolled at the Ma-
con, GA site, added an arm assigning 400 μg/day Se supplementation in order
to evaluate the effects of high Se exposure and possible dose-response trends
[123]. The results showed a possible limited decrease of risk of nonmelanoma
skin cancer in the 400 μg Se supplemented individuals (RR 0.88, 95% CI
0.66–1.16), compared with the excess incidence observed in the 200 μg/day
participants (RR 1.49, 95% CI 1.10–2.03), and no indication of decreased all-
cancer incidence as seen in the NPC main results, with a RR of 1.10 (95%
CI 0.57–2.17) (Figure 2-c). These results appear to weaken the NPC findings,
although they lack statistical precision.
A trial carried out in a French population of 184 organ graft recipients,
considered to be at high risk of premalignant and malignant epithelial lesions,
unexpectedly detected a higher incidence of skin cancer in the 91 Se-treated
patients (6 cases, 6.6%) than in the 93 placebo patients (2 cases, 2.2%, P= 0.15)
during 5-year follow-up, the first 3 of which including daily supplementation
with 200 μg Se as selenized yeast [98] (Figure 2-c). Thus this study suggests
an increased risk of skin cancer, mirroring the results of the NPC study [94]
and of some although not all observational studies [55, 121].
Another randomized double-blind trial of considerable interest was con-
ducted in Poland with a group of healthy women who were carriers of
the BRCA1 mutation and thus at high risk for breast cancer [101]. Lu-
binski and colleagues randomized 1135 female BRCA1 mutation carriers to
250 μg/day of Se as selenite or placebo for 6 to 62 months (median follow-
up 35 months). During follow-up, 60 incident breast cancers were diagnosed
among Se-supplemented women in comparison with 45 cases among placebo-
administered women (RR 1.4, 95% CI 0.9–2.0) [101]. Such results, which were
mirrored in findings on primary breast cancer, contralateral breast cancer, and
ovarian cancer, suggest not just a lack of any beneficial effect of Se on breast
cancer in these high-risk women but the possibility of increased risk.
Two phase III trials have published findings on the effect of Se on prostate
cancer risk for high-risk individuals, which distinguishes these studies from
the SELECT trial. Results of these studies, and more generally of the trials
investigating prostate cancer risk, are reported in Figure 2-b. The first study,
coordinated by the Southwest Oncology Group [96], randomized 423 men with
high-grade prostatic intraepithelial neoplasia to 200 μg/day Se as selenome-
thionine or placebo. After a treatment period with follow-up of 3 years, the
incidence of prostate cancer in the two groups was nearly identical (48/135
[35.6%] in the Se group vs. 49/134 [36.6%] in the placebo group). There was
little evidence of modifying effects of baseline plasma Se status on prostate
cancer risk. In fact, lower risk emerged in the bottom (<106 μg/l) and top
(>162 μg/l) quartiles of plasma Se, where RRs were 0.82 (95% CI 0.40–1.69)
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and 0.91 (95% CI 0.45–1.84), respectively, while individuals in the second quar-
tile (106–132 μg/l) showed a RR of 1.38 (95% CI 0.68–2.78). When the study
sample was stratified by Gleason score of diagnosed prostate cancer, there was
a tendency toward more aggressive tumors among Se-treated subjects. Overall,
the authors concluded there was no effect of Se supplementation on prostate
cancer risk in this high-risk population, although they did not entirely rule out
the possibility of a beneficial effect in the lowest category of Se exposure. These
results are similar to results from a recently reported Canadian phase III trial
of patients with high-grade prostatic intraepithelial neoplasia, in which 3-year
supplementation with vitamin E, soy, and Se (100 μg/day) was associated with
a prostate cancer RR of 1.12 (95% CI 0.71–1.76) [124].
A second phase III trial, the Negative Biopsy Study, enrolled individu-
als from the United States and New Zealand at high risk of prostate cancer
(PSA >4 ng/ml and/or suspicious digital rectal examination and/or PSA veloc-
ity >0.75 ng/ml/year) but with a prostate biopsy negative for cancer or high-
grade intraepithelial neoplasia, who were randomized to 200 or 400 μg/day Se
as selenized yeast or placebo [125]. The results of this 5-year trial [97] sug-
gested no effect of Se treatment on prostate cancer incidence, which was 11.3%
(26 cases) among 228 placebo-randomized subjects, 10.3% (24/233) among sub-
jects receiving 200 μg/day Se, and 10% (23/230) among those supplemented
with 400 μg/day Se. No effect of Se status at baseline on risk emerged, despite
the fact that the lowest category had a plasma Se concentration of less than
101.1 μg/l. Additionally, little evidence of any effect of the Se treatment on PSA
velocity emerged. Therefore, it is difficult not to agree with authors’ conclusion
that “Selenium supplementation appeared to have no effect on the incidence of
prostate cancer in men at high risk. In conjunction with results of other stud-
ies, these data indicate that selenium supplementation may not have a role in
prostate cancer chemoprevention” [97].
Lack of replication of the original NPC results by the SELECT trial, the
results of two phase III trials of high prostate cancer risk patients, and the
weakening results of the NPC trial itself over time indicate that prospective
observational studies suggesting a beneficial effect of baseline Se status on
subsequent prostate cancer risk [50] were likely biased by unmeasured con-
founders, and that Se does not modify prostate cancer risk. However, the pos-
sibility of modifying effects of specific genotypes [126] or of possible adverse
effects of very low and very high Se exposures deserve further investigation.
This may be possible using SELECT trial data and biological specimens (blood
and toenails) to assess baseline Se status in study participants.
Over and above these null findings, recent findings of observational studies
suggest extreme caution is needed when considering the effect of Se-containing
supplements on prostate cancer risk. In fact, cohort and case-control studies
have shown an unexpectedly increased prostate cancer risk among Se-treated
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subjects with the highest baseline exposure levels [105], excess risk associ-
ated with multivitamin use only among Se supplements use [127], an excess
prostate cancer risk associated with Se self-supplementation (OR 2.2 with 95%
CI 1.2–4.2 among consumers for ≥10 yrs. of Se supplements) [128], and finally
a higher risk of aggressive disease in patients with higher plasma Se levels
[85].
Results of a Natural Experiment on Selenium Exposure
Natural experiments, of which Snow’s study on cholera remains the
archetype, have long enjoyed a privileged position in environmental epidemi-
ology, since they allow the study of toxic substances that cannot be admin-
istered to humans for ethical reasons or that may require such long periods
of exposure as to make them infeasible [129]. Such a natural experiment oc-
curred in the Northern Italy community of Reggio Emilia, where the Rivalta
neighborhood was supplied from 1972 to 1988 with municipal tap water con-
taining unusually high levels of Se in its inorganic hexavalent form, selenate,
which was the only distinctive chemical characteristics compared to drinking
water distributed in the remaining municipal territory [119, 130]. The Rivalta
residents also had a very similar distribution of demographic characteristics
compared with the municipal population, suggesting limited potential for bias
[119, 130]. Results of cohort studies carried out among long-term consumers of
this high-Se tap water are summarized in Figure 3. Overall, no beneficial effect
on mortality from cancer or other chronic diseases emerged: cancer mortality,
in fact, was slightly increased (RR 1.20, 95% CI 1.01–1.41), with excess mortal-
ity from melanoma and colorectal cancer in the whole cohort, kidney cancer in
males and lympho-hematopoietic malignancies in females [119], and further
confirmation of the increased melanoma risk from an incidence study [121].
Prostate cancer mortality was not decreased, but rather increased, among ex-
posed residents (RR 1.40, 95% CI 0.45–3.39).
Overall, these findings suggest no beneficial effect of Se on cancer risk,
but rather the potential for adverse effects. These results, however, have to be
considered specific for the inorganic hexavalent form of Se, whose biological
properties may be markedly different from those of other chemical forms of Se
such as selenomethionine, an organic form commonly used in human trials.
Absolute amounts of Se exposure across the different chemical species cannot
be directly compared, as demonstrated by laboratory studies that show that
toxicity of inorganic (tetravalent) Se greatly exceeds that of organic Se [131].
However, these results are of interest since they allow assessment of the ef-
fect of the Se form usually found in drinking water, the inorganic hexavalent
one, on cancer risk, and allow risk assessment of such sources of exposure
[132].
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Figure 3: Relative risk (RR) for selected cancers in a natural experiment investigated in
Reggio Emilia, northern Italy, where residents consumed drinking water with high inorganic
hexavalent Se content (around 8 μg/l) as only distinctive feature (Vinceti et al., 1995, 1998,
and 2000 [119, 121, 130]).
WHAT LEVEL OF SE EXPOSURE IS “SAFE”?
Given the nutritional role of Se and its possible low-dose toxic effects, the
questions arise: What level of Se exposure in humans is needed for adequate
nutrition, and at what level does Se exposure carry health risks? These are
open questions, as demonstrated by the different upper and lower safe limits
that have been proposed by various agencies, institutions, and investigators
[133, 134], for both nutritional [135] and toxicological [5] effects, such as for Se
drinking water standards [132].
Many current standards are based on outdated approaches and evidence.
For example, one frequently used indicator of a “safe” Se exposure level and of a
nutritional range of intake is the Se-induced increases and maximization of se-
lenoproteins such as the Se-containing glutathione-peroxidases. We agree with
a World Health Organization research group that such an approach should
be regarded with extreme caution [135]. Recent studies indicate the complex-
ity of this issue at the molecular level [136]. Maximization of Se-containing
glutathione-peroxidases has never been demonstrated to be beneficial, and
more generally, maximal expression of antioxidant enzymes should not be con-
sidered beneficial for human health unless a sound epidemiologic basis has
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been provided for this [5, 137]. Epidemiologic data suggest adverse health ef-
fects of Se at levels lower than those required to maximize selenoprotein ex-
pression [114, 119, 138, 139], and biochemical studies have long indicated that
increased selenoprotein activity, such as in the case of glutathione-peroxidases,
is driven not only by increased Se availability but also by oxidative stress in-
duced by Se itself or by other environmental or biological stressors [45–48,
140, 141]. In line with this hypothesis, Se supplementation has been shown
to increase levels of some proteins in adult men including clusterin [142], an
enzyme that may be induced by oxidative stress [143, 144], and recent cross-
sectional studies confirmed a direct relationship between Se exposure and ox-
idative stress biomarkers [145, 146].
Perhaps the best available evidence on toxic effects of Se and the levels
of intake associated with them comes from observations—sometimes entirely
unexpected—in human experimental studies [94, 99, 104, 114, 120]. Currently,
the main concerns of adverse effects of Se exposure [115, 147] are an excess of
skin cancer [94, 98], diabetes [99, 114, 139], and dermatologic alterations [99];
increased risk of glaucoma [120, 148, 149] and amyotrophic lateral sclerosis
[8, 150] may also occur after low-dose overexposure to organic and inorganic
Se, respectively, consistent with laboratory evidence [45, 151, 152]. Toxicity of
inorganic Se appears to be higher than toxicity of organic forms, in line with
observations from laboratory studies [67, 131, 153], possibly being as low as
around 20 μg/day on the basis of epidemiologic observations in long-term con-
sumers of drinking water with high content of hexavalent Se [119, 154], which
represents one of the few natural sources of exposure to this inorganic Se form.
Additional consequences of low-dose Se overexposure may be other endocrine
abnormalities or adverse effects to other organs [5, 155] and down-regulation
of phase 2 genes [156], although evidence for these effects and identification
of the thresholds of exposure involved have not been convincingly provided so
far.
Currently proposed “safe” upper limits are not convincingly “safe” by cur-
rent evidence; for example, the safe upper limit of intake of 400 μg/day in
adults suggested in 2000 by the Institute of Medicine [133] appears inadequate
to protect human health in light of the SELECT trial results showing toxic ef-
fects of (organic) Se exposure at around 300 μg/day [99], and other epidemio-
logic studies for organic Se and inorganic Se, with the latter being especially
of concern for toxicity at such levels [5, 114, 139, 150, 157, 158]. Therefore, al-
though the 2009 statement by Platz and Lippman that “At present, we do not
know enough to determine how much selenium any man or woman should re-
ceive from the diet or a supplement” [159] is certainly and unfortunately true,
the epidemiologic evidence from the most recent studies suggest that the safe
range of intake of dietary Se is much lower than anticipated for the organic Se
forms and much, much lower for inorganic species [5].
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SELENIUM AS A POTENTIAL CANCER THERAPEUTIC AGENT
The fading promise of a cancer-preventive effect of Se has been accompanied by
rising interest in its potential ability to reduce cancer recurrence or to directly
treat cancer in diagnosed patients, in line with a larger interest in the possible
therapeutic properties of Se for various diseases [160].
The objective of preventing cancer recurrence is relatively new and differs
from the objective of the NPC trial, which aimed to assess whether Se could
reduce the occurrence of new cancers in nonmelanoma skin cancer patients
rather than the risk of recurrence [102]. One study evaluating this new ob-
jective is the SELEnium and BLAdder cancer Trial (SELEBLAT), a phase III
randomized, placebo-controlled, double-blind trial designed to assess the abil-
ity of Se to reduce recurrences of noninvasive transitional bladder carcinoma
[161]. This trial is currently ongoing, and its findings, whether negative or pos-
itive, will certainly add to the debate about Se.
The ability of certain Se species to exert toxic effects on cancer cell growth
has been demonstrated in a number of laboratory studies [162–171], leading
to interest in the use of Se compounds as anticancer therapeutic agents, possi-
bly as additions to standard chemotherapeutic regimens [165, 172–174]. Some
Se compounds have been shown to exert specific activities against cancer cells
compared to normal cell [175], although these findings have not always been
confirmed [176]. The number of human studies in this area is still very lim-
ited. A trial conducted in non-Hodgkin lymphoma patients reported that the
addition of selenite to chemotherapy appeared to reduce recurrence risk [177].
On the other hand, a study involving stage-I nonsmall cell lung cancer pa-
tients failed to show beneficial results on risk of second primary tumors [178],
and self-administration of Se supplements did not reduce recurrence outcomes
among prostate cancer patients enrolled in the TAX 327 study [179]. On a
cautionary note, a review of the use of dietary antioxidant supplementation
during conventional chemotherapy and radiation therapy concluded that the
use of such supplements should be discouraged because of the possibility of
tumor protection and reduced survival [180].
The current evidence is too limited and inconsistent [181] to allow for an
adequate assessment of Se as an anticancer agent and to justify its adminis-
tration in cancer therapy, although this issue remains relevant and merits fur-
ther evaluation. The complexity of this issue is highlighted by a recent study
in mice, which showed that organic Se supplementation reduced and delayed
breast cancer metastasis while selenite exacerbated it [182], confirming again
that it is of utmost importance to consider the chemical form-specific effects of
Se. Further studies and particularly human trials, taking into account clinical
disease stage and genetic factors, are required to better investigate the utility
and safety of Se compounds as cancer therapeutic agents.
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FINAL CONSIDERATIONS
The trajectory of opinion on the relationship between Se and cancer over the
years could be encapsulated in the study of lung cancer. Studies suggested a
beneficial effect of Se on lung cancer risk until a decade ago [183], when fur-
ther studies [99] failed to substantiate such an effect. Further, a recent obser-
vational study found a direct relationship between Se exposure and risk [58],
mirroring previous results obtained in a U.S. study [53], and Se has now been
added to the list of initially promising but ultimately unsuccessful—and pos-
sibly harmful—preventive agents for lung cancer [178, 184]. In Se, we have
witnessed what has now become a common occurrence in nutritional epidemi-
ology, the failure of micronutrient dietary supplements to show beneficial ef-
fects on human health [185–187].
Overall, experimental human studies indicate that Se does not reduce can-
cer risk and may increase risk of some site-specific cancers such as skin neo-
plasms, and no convincing evidence has so far been provided that individuals
with “low” Se intake, that is, in the order of 20–70 μg/day, may reduce can-
cer risk by increasing their Se exposure. Taking into account the potential for
harm at very low levels of intake, no dietary or environmental supplementa-
tion with this metalloid may be currently recommended for cancer prevention
from either an individual or a public health perspective.
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